Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

Схожие документы

• Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
  по: Zhuang, Xibin, et al.
  Опубликовано: (2019)
• Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
  по: Zhao, Chao, et al.
  Опубликовано: (2020)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  по: Jia, Yijun, et al.
  Опубликовано: (2020)
• High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients
  по: Zhao, Chao, et al.
  Опубликовано: (2015)
• The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
  по: Zhao, Chao, et al.
  Опубликовано: (2020)